SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline

Brookline Capital Markets analyst Kemp Doliver reiterated a Buy rating and $44.64 price target on SCYNEXIS (NASDAQ: SCYX).

The analyst comments "FDA’s daily update of Drug Safety-related Labeling Changes includes changes to BREXAFEMME’s label. The changes themselves are not significant but rather the action itself is concrete evidence that GSK is closer to relaunching BREXAFEMME. Our model assumes relaunch in H2:2026 with $2.5MM of royalty revenue in Q4:2026 and $17MM in milestone and royalties in 2027. GSK’s payments to SCYX represent $13 of our Target Price based on peak revenue of $672MM globally in 2026 (10% discount rate). Resumption of these payments would extend the cash runway past mid-2029. We have an inquiry into SCYX management for additional color. We reiterate our Buy rating and our Target Price of $44.64."

For an analyst ratings summary and ratings history on SCYNEXIS click here. For more ratings news on SCYNEXIS click here.

Shares of SCYNEXIS closed at $3.73 yesterday.

You May Also Be Interested In

• U.S. lawmakers ask DoorDash about use of China AI models - CNBC
• Cantor Fitzgerald Reiterates Neutral Rating on GoDaddy Inc (GDDY)
• Starbucks (SBUX) PT Raised to $115 at Freedom Broker